Richard A. Larson to Cyclin-Dependent Kinase Inhibitor p21
This is a "connection" page, showing publications Richard A. Larson has written about Cyclin-Dependent Kinase Inhibitor p21.
Connection Strength
0.030
-
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs. 2015 Apr; 33(2):371-9.
Score: 0.030
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.